All In Biotech

Drug Trial Radar · NCT05763550

To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Herpetic Neuralgia

A Multicenter, Randomized, Double-Blind, Double-Dummy , Pregaballin-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of HSK16149 Capsules in Chinese Patients With Herpetic Neuralgia

Last checked: Nov 20, 2026Latest source record: Nov 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 331 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

331

Actual

Start

Feb 27, 2023

Primary completion

Jun 22, 2023

Study completion Aug 7, 2023

Sponsor

Sponsor type
Industry
First posted
Mar 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Investigate the efficacy and safety of HSK16149 capsules in Chinese herpetic Neuralgia following 4 weeks treatment in comparison to pregabalin.

Conditions

  • Herpetic Neuralgia

Interventions

  • HSK16149 20mg BIDDrug

    HSK16149 20mg, orally twice a day, treatment period; 4-weeks fixed dose.

  • HSK16149 40mg BIDDrug

    HSK16149 40mg, orally twice a day, treatment period; 4-weeks fixed dose.

  • Pregabalin 150mgDrug

    pregabalin, orally twice a day, treatment period; 150 mg (75 mg twice daily) for 1 week;300 mg (150 mg twice daily) daily for 3 week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare the change from baseline in Numeric Rating Scales(NRS )between HSK16149 and pregabalin at week 4Time frame: Baseline and week 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.